ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.

$35.43  -0.68 (-1.87%)
As of 09/17/2021 11:17:24 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  04/28/2017
Outstanding shares:  46,385,729
Average volume:  459,436
Market cap:   $1,532,120,629
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    98985W102
ISIN:        CA98985W1023
Sedol:      BYQHPK7
Valuation   (See tab for details)
PE ratio:   -7.52
PB ratio:   5.19
PS ratio:   300.60
Return on equity:   -57.45%
Net income %:   -3,623.23%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy